CHAPEL HILL, N.C.--(BUSINESS WIRE)--Dec. 8, 2004--POZEN Inc.
(NASDAQ: POZN) announced today the appointment of William Stagner,
R.Ph., Ph.D, an executive with 25 years of pharmaceutical development
experience, as senior vice president, program management and
development planning. Dr. Stagner will be responsible for management
of the company's project development teams and programs.
"Bill is an outstanding pharmaceutical executive who brings to
POZEN years of experience in the management of pharmaceutics,
preclinical, and clinical development programs, as well as experience
as a general manager," said Dr. John R. Plachetka, POZEN's chairman,
president, and chief executive officer.
Dr. Stagner was most recently employed at Cardinal Health
Pharmaceutical Development (formerly Magellan Labs) as senior vice
president and general manager. Prior to joining Cardinal Health in
1999, Dr. Stagner held several executive positions at GlaxoWellcome,
Inc., including group director, dermatology research and development,
and pharmaceutics director for Glaxo Research Institute. Before
joining Glaxo, Dr. Stagner was with Merrell Dow Research Institute.
During his tenure with Glaxo, Dr. Stagner was responsible for
directing all dermatology product development activities for
investigational and marketed products, as well as leading their
discovery, preclinical, medical and regulatory efforts. While at Glaxo
Research Institute and Cardinal Health he founded their pharmaceutics
divisions. He has been on teams responsible for the approval of over
25 new drug applications (NDAs).
Dr. Stagner received his B.S., M.S., and Ph.D. degrees from the
University of Iowa, College of Pharmacy.
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. Since its
inception, POZEN has focused its efforts primarily on the development
of pharmaceutical products for the treatment of migraine. POZEN is
also exploring the development of product candidates in other
pain-related therapeutic areas. POZEN has development and commercial
alliances with GlaxoSmithKline, Xcel Pharmaceuticals, and Nycomed. The
company's common stock is traded on The Nasdaq Stock Market under the
symbol "POZN". For detailed company information, including copies of
this and other press releases, see POZEN's website: www.pozen.com.
Statements included in this press release that are not historical
in nature are "forward-looking statements" within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are subject
to a number of risks and uncertainties, including, but not limited to,
our failure to successfully commercialize our product candidates;
costs and delays in the development and/or FDA approval of our product
candidates, including as a result of the need to conduct additional
studies, or the failure to obtain such approval of our product
candidates; uncertainties in clinical trial results or the timing of
such trials, resulting in, among other things, an extension in the
period over which we recognize deferred revenue or our failure to
achieve milestones that would have provided us with revenue; our
inability to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements necessary
for the development, manufacture, commercialization, marketing, sales
and distribution of any products; competitive factors; our inability
to protect our patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property to operate our
business; our inability to operate our business without infringing the
patents and proprietary rights of others; general economic conditions;
the failure of any products to gain market acceptance; our inability
to obtain any additional required financing; technological changes;
government regulation; changes in industry practice; and one-time
events, including those discussed herein and in our Quarterly Report
on Form 10-Q for the quarterly period ended September 30, 2004 under
"Management's Discussion and Analysis of Financial Condition and
Results of Operations." We do not intend to update any of these
factors or to publicly announce the results of any revisions to these
CONTACT: POZEN Inc.
Chief Financial Officer
Director, Investor Relations
SOURCE: POZEN Inc.